Wolfe将礼来的目标价从1250美元上调至1325美元,评级“跑赢大市”,预计长期需求强劲且公司将继续主导减肥药物市场。
Wolfe将礼来的目标价从1250美元上调至1325美元,评级“跑赢大市”,预计长期需求强劲且公司将继续主导减肥药物市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.